Leading the Way in Life Science Technologies

GEN Exclusives

More »

Tutorials

More »

For full access to this article login to GEN Select now.

May 1, 2014 (Vol. 34, No. 9)

Closed Processing for Cell Therapies

Engineering Risk Reduction and Patient Safety during Manufacturing

  • Production of patient-specific cell-based therapies (PSCT) presents unique scale and cost challenges not seen in pharmaceuticals and biologics manufacturing. Rather than scaling up to ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »